Back to Journals » Drug, Healthcare and Patient Safety » Volume 2

TNF-α inhibitors: are they carcinogenic?

Authors Raval G, Mehta P

Published 6 December 2010 Volume 2010:2 Pages 241—247


Review by Single anonymous peer review

Peer reviewer comments 2

Girindra Raval1, Paulette Mehta2,3
1Jefferson Regional Medical Center, Jefferson Hills, PA, USA; 2Department of Internal Medicine (Hematology/Oncology), UAMS, Little Rock, AR, USA; 3Central Arkansas Veterans Healthcare System, Little Rock, AR, USA

Abstract: Biologic therapy has increasingly been used in the treatment of chronic diseases. Tumor necrosis factor (TNF) is a cytokine implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Anti-TNF therapy is being used in the treatment of these conditions. Since the introduction of anti-TNF agents, there have been many case reports of development of malignancy after the initiation of anti-TNF therapy. With increasing case reports, there is growing concern that anti-TNF therapy, albeit useful in the treatment of these chronic conditions, might be associated with the development of malignancy in patients. In this review we examine the different anti-TNF agents and different studies to evaluate any possible association between use of any anti-TNF agent and development of malignancy.

Keywords: tumor necrosis factor inhibitor, malignancy, rheumatoid arthritis, inflammatory bowel disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]